BP
Biopharmaceutical company developing transformative medicines for patients with genetic diseases and cancers.
About
BridgeBio is a biopharmaceutical company focused on bringing meaningful medicines to patients quickly and safely. They develop and deliver treatments for genetic diseases, with a pipeline that includes approved medicines like Attruby® (acoramidis) and NULIBRY® (fosdenopterin), as well as investigational therapies for conditions such as Transthyretin Amyloidosis and Limb-Girdle Muscular Dystrophy. BridgeBio serves patients by advancing a diverse pipeline of therapeutic candidates from discovery through to commercialization.
Tags
Total Employees
875
Current headcount
Performance
Company Timeline
No timeline data for this period
Score Breakdown
35Traction
20Team
30Visibility
8Profile
0Community
0Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does BridgeBio Pharma do?
BridgeBio is a biopharmaceutical company focused on bringing meaningful medicines to patients quickly and safely. They develop and deliver treatments for genetic diseases, with a pipeline that includes approved medicines like Attruby® (acoramidis) and NULIBRY® (fosdenopterin), as well as investigational therapies for conditions such as Transthyretin Amyloidosis and Limb-Girdle Muscular Dystrophy. BridgeBio serves patients by advancing a diverse pipeline of therapeutic candidates from discovery t…
Where is BridgeBio Pharma headquartered?
BridgeBio Pharma is headquartered in Palo Alto, United States.
When was BridgeBio Pharma founded?
BridgeBio Pharma was founded in 2015.
What industry does BridgeBio Pharma operate in?
BridgeBio Pharma operates in Biotech, Pharmaceuticals, Healthcare.
How many employees does BridgeBio Pharma have?
BridgeBio Pharma has approximately 875 people on record.
What is BridgeBio Pharma's current status?
BridgeBio Pharma's current operating status is: Public.
Similar Startups